Clinical study on vedolizumab combined with sulfasalazine in treatment of moderate to severe ulcerative colitis
Objective To evaluate the clinical efficacy of vedolizumab combined with sulfasalazine in treatment of moderate to severe ulcerative colitis. Methods Patients (99 cases) with moderate to severe ulcerative colitis in Beijing No.6 Hospital from August 2021 to August 2023 were randomly divided into control (49 cases) and treatment (50 cases) group. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets,the initial dose was 1 g/d,if tolerated,increased to 2 g,three times daily,and decreased to 1 g/d after remission,twice daily. Patients in the treatment group were iv administered with Vedolizumab for injection on the basis of the control group,once at weeks 0,2,6,and 14 respectively,300 mg was added into 250 mL of physiological saline,the infusion duration was controlled to more than 30 min. Patients in two groups were treated for 14 weeks. After treatment,the clinical evaluations were evaluated,the clinical symptom improvement time,the scores of UCEIS,DAI and IBDQ,the levels of intestinal mucosal shield function indicators DAO,BE and β-DF,and the levels of serum I-FABP,MCP-1 and HSP70 in two groups before and after treatment were compared. Results After treatment,the total clinical effective rates in the control group and the treatment group were 81.63％ and 96.00％,respectively,and the difference between the two groups was statistically significant (P<0.05). After treatment,the improvement time for patients in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment,the UCEIS score and DAI score were significantly decreased significantly in two groups,while the IBDQ score was significantly increased (P<0.05),and the improvement of scores in the treatment group was more prominent (P<0.05). After treatment,the levels of intestinal mucosal shielding function indicators DAO,BE,β-DF,I-FABP and MCP-1 in two groups were significantly reduced,while the serum HSP70 levels were significantly increased (P<0.05),and the treatment group showed more prominent improvement in these indicators (P<0.05). Conclusion Vidlizumab combined with sulfasalazine has significant efficacy in the treatment of moderate to severe ulcerative colitis. It can not only significantly improve the patient's clinical symptoms,disease severity and quality of life,but also improve the patient's intestinal mucosa shielding function and promote serological indicators.
Vedolizumab for injectionSulfasalazine Enteric-coated Tabletsmoderate to severe ulcerative colitisintestinal mucosa shielding functionI-FABPHSP70
NETL
NSTL
万方数据
